Idera Pharmaceuticals, Inc.
USE OF A TLR9 AGONIST IN METHODS FOR TREATING COVID-19
Last updated:
Abstract:
The present invention is directed to use of tilsotolimod in the treatment of coronavirus infection, for example, SARS-CoV2, and COVID-19.
Status:
Application
Type:
Utility
Filling date:
9 Apr 2021
Issue date:
14 Oct 2021